SI2970447T1 - Protitelesa proti pan-elr+ cxc kemokinom - Google Patents
Protitelesa proti pan-elr+ cxc kemokinom Download PDFInfo
- Publication number
- SI2970447T1 SI2970447T1 SI201430741T SI201430741T SI2970447T1 SI 2970447 T1 SI2970447 T1 SI 2970447T1 SI 201430741 T SI201430741 T SI 201430741T SI 201430741 T SI201430741 T SI 201430741T SI 2970447 T1 SI2970447 T1 SI 2970447T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- hcvr
- Prior art date
Links
- 108050006947 CXC Chemokine Proteins 0.000 title abstract 2
- 102000019388 CXC chemokine Human genes 0.000 title abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 206010038389 Renal cancer Diseases 0.000 claims abstract 2
- 201000010982 kidney cancer Diseases 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims 1
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 claims 1
- -1 Grogama Proteins 0.000 claims 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 claims 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 102100036154 Platelet basic protein Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000055297 human CXCL1 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010037575 Pustular psoriasis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000013781 human elastin-laminin receptor Human genes 0.000 abstract 1
- 108010064955 human elastin-laminin receptor Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 abstract 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Claims (12)
- PROTITELESA PROTI PAN-ELR+ CXC KEMOKINOM Patentni zahtevki1. Protitelo, ki veže človeški Gro-alfa, Gro-beta, Gro-gama, ENA-78, GCP-2, NAP-2, in IL-8, protitelo vključuje lahko verigo in težko verigo, pri čemer lahka veriga vključuje variabilno regijo lahke verige (LCVR) in težka veriga vključuje variabilno regijo težke verige (HCVR), pri čemer LCVR vključuje LCDR1, LCDR2, LCDR3 in HCVR vključuje HCDR1, HCDR2, HCDR3, kjer je LCDR1 RASOSISNNLH (SEQ ID NO: 7), LCDR2 je YTSRSVS (SEQ ID NO: 8), LCDR3 je GQNNEWPEV (SEQ ID NO: 9), HCDR1 je GYEFTSYWIH (SEQ ID NO: 10), HCDR2 je NISPNSGSANYNEKFKS (SEQ ID NO: 11), in HCDR3 je EGPYSYYPSRXaaYYGSDL (SEQ ID NO: 20), pri čemer je Xaa E ali Q.
- 2. Protitelo po zahtevku 1, pri čemer je aminokislinsko zaporedje HCVR SEQ ID NO: 2.
- 3. Protitelo po zahtevku 1, pri čemer je aminokislinsko zaporedje LCVR SEQ ID NO: 4.
- 4. Protitelo po zahtevku 1, pri čemer je aminokislinsko zaporedje HCVR SEQ ID NO: 2 in je aminokislinsko zaporedje LCVR SEQ ID NO: 4.
- 5. Protitelo po zahtevku 1, pri čemer je aminokislinsko zaporedje težke verige SEQ ID NO: 1 in je aminokislinsko zaporedje lahke verige SEQ ID NO: 3.
- 6. Protitelo po zahtevku 1, pri čemer protitelo vključuje dve težki verigi z aminokislinskim zaporedjem SEQ ID NO: 1 in dve lahki verigi z aminokislinskim zaporedjem SEQ ID NO: 3.
- 7. DNK molekula, ki vključuje prvo polinukleotidno zaporedje, ki kodira polipeptid z aminokislinskim zaporedjem SEQ ID NO: 1; in ki vključuje drugo polinukleotidno zaporedje, ki kodira polipeptid z aminokislinskim zaporedjem SEQ ID NO: 3.
- 8. Sesalska celica, ki vključuje DNK molekulo po zahtevku 7, pri čemer je celica sposobna izražanja protitelesa po kateremkoli izmed zahtevkov od 1 do 6.
- 9. Postopek proizvodnje protitelesa po kateremkoli izmed zahtevkov od 1 do 6, postopek vključuje gojenje sesalskih celic po zahtevku 8 v pogojih, ki omogočajo izražanje protitelesa, in pridobivanje izraženega protitelesa.
- 10. Protitelo proizvedeno s postopkom po zahtevku 9.
- 11. Protitelo po kateremkoli izmed zahtevkov od 1 do 6 in 10 za uporabo v terapiji.
- 12. Protitelo po kateremkoli izmed zahtevkov od 1 do 6 in 10 za uporabo pri zdravljenju ulceroznega kolitisa, raka ledvic ali raka jajčnikov.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792800P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/020605 WO2014149733A1 (en) | 2013-03-15 | 2014-03-05 | Pan-ELR+ CXC CHEMOKINE ANTIBODIES |
| EP14711899.6A EP2970447B1 (en) | 2013-03-15 | 2014-03-05 | Pan-elr+ cxc chemokine antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2970447T1 true SI2970447T1 (sl) | 2018-06-29 |
Family
ID=50343858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430741T SI2970447T1 (sl) | 2013-03-15 | 2014-03-05 | Protitelesa proti pan-elr+ cxc kemokinom |
Country Status (35)
| Country | Link |
|---|---|
| EP (4) | EP4467566A3 (sl) |
| JP (1) | JP6105146B2 (sl) |
| KR (1) | KR101745230B1 (sl) |
| CN (2) | CN105143259B (sl) |
| AP (1) | AP2015008731A0 (sl) |
| AR (2) | AR094960A1 (sl) |
| AU (1) | AU2014237898B2 (sl) |
| CA (1) | CA2901468C (sl) |
| CL (1) | CL2015002531A1 (sl) |
| CY (1) | CY1120459T1 (sl) |
| DK (1) | DK2970447T3 (sl) |
| EA (1) | EA029965B1 (sl) |
| ES (3) | ES2675404T3 (sl) |
| HR (1) | HRP20181047T1 (sl) |
| HU (1) | HUE038834T2 (sl) |
| IL (2) | IL241167B (sl) |
| JO (1) | JO3580B1 (sl) |
| LT (1) | LT2970447T (sl) |
| MA (1) | MA38413A1 (sl) |
| ME (1) | ME03094B (sl) |
| MX (1) | MX364831B (sl) |
| MY (1) | MY171213A (sl) |
| NZ (1) | NZ711704A (sl) |
| PE (2) | PE20191480A1 (sl) |
| PH (1) | PH12015502090B1 (sl) |
| PL (1) | PL2970447T3 (sl) |
| PT (1) | PT2970447T (sl) |
| RS (1) | RS57291B1 (sl) |
| SG (1) | SG11201507686TA (sl) |
| SI (1) | SI2970447T1 (sl) |
| TN (1) | TN2015000377A1 (sl) |
| TR (1) | TR201807613T4 (sl) |
| TW (1) | TWI612059B (sl) |
| UA (1) | UA116008C2 (sl) |
| WO (1) | WO2014149733A1 (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911600C (en) * | 2013-05-17 | 2025-02-04 | Centre National De La Recherche Scientifique (Cnrs) | Antibodies against CXCL1, CXCL7 and CXCL8 and their applications |
| EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
| JP2021510697A (ja) | 2018-01-12 | 2021-04-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療 |
| KR102049180B1 (ko) * | 2018-04-02 | 2019-11-26 | 고려대학교 산학협력단 | 체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법 |
| TWI737000B (zh) * | 2018-10-22 | 2021-08-21 | 美商美國禮來大藥廠 | 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體 |
| CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
| CN113087795B (zh) * | 2019-12-23 | 2025-06-10 | 上海普铭生物科技有限公司 | 针对趋化因子cx3cl1的抗体及其应用 |
| US20230137966A1 (en) * | 2020-02-12 | 2023-05-04 | Eli Lilly And Company | Crystallization of Antibodies or Antigen-Binding Fragments |
| TW202206457A (zh) * | 2020-04-24 | 2022-02-16 | 美商美國禮來大藥廠 | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 |
| CN112358547A (zh) * | 2020-09-30 | 2021-02-12 | 浙江大学 | 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用 |
| WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| WO2007107003A1 (en) * | 2006-03-22 | 2007-09-27 | Osteopharm Inc. | Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| NO2195023T3 (sl) * | 2007-08-29 | 2018-08-04 | ||
| GB0806812D0 (en) * | 2008-04-15 | 2008-05-14 | Univ Leuven Kath | Citrullinated cytokines |
| AU2009246683A1 (en) * | 2008-05-14 | 2009-11-19 | Eli Lilly And Company | Anti-CXCR4 antibodies |
| ES2531561T3 (es) * | 2009-08-28 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de antiquina que se enlazan a múltiples quimioquinas CC |
| JP2011097867A (ja) * | 2009-11-05 | 2011-05-19 | Kurume Univ | 脊柱靱帯骨化症のマーカーペプチド |
| WO2011100271A2 (en) * | 2010-02-09 | 2011-08-18 | Glaxosmithkline Llc | Novel uses |
| JP6211597B2 (ja) * | 2012-05-01 | 2017-10-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規抗体 |
-
2014
- 2014-02-27 TW TW103106908A patent/TWI612059B/zh active
- 2014-02-27 JO JOP/2014/0058A patent/JO3580B1/ar active
- 2014-02-28 AR ARP140100675A patent/AR094960A1/es active IP Right Grant
- 2014-03-05 CN CN201480013248.XA patent/CN105143259B/zh active Active
- 2014-03-05 CN CN201811074266.5A patent/CN109134652B/zh active Active
- 2014-03-05 EP EP24199045.6A patent/EP4467566A3/en active Pending
- 2014-03-05 LT LTEP14711899.6T patent/LT2970447T/lt unknown
- 2014-03-05 CA CA2901468A patent/CA2901468C/en active Active
- 2014-03-05 MX MX2015013053A patent/MX364831B/es active IP Right Grant
- 2014-03-05 MY MYPI2015703113A patent/MY171213A/en unknown
- 2014-03-05 EP EP18153438.9A patent/EP3348569B1/en active Active
- 2014-03-05 EP EP14711899.6A patent/EP2970447B1/en active Active
- 2014-03-05 EP EP19190355.8A patent/EP3608336B1/en active Active
- 2014-03-05 HU HUE14711899A patent/HUE038834T2/hu unknown
- 2014-03-05 DK DK14711899.6T patent/DK2970447T3/en active
- 2014-03-05 PE PE2019001763A patent/PE20191480A1/es unknown
- 2014-03-05 MA MA38413A patent/MA38413A1/fr unknown
- 2014-03-05 AP AP2015008731A patent/AP2015008731A0/xx unknown
- 2014-03-05 KR KR1020157024786A patent/KR101745230B1/ko active Active
- 2014-03-05 WO PCT/US2014/020605 patent/WO2014149733A1/en not_active Ceased
- 2014-03-05 AU AU2014237898A patent/AU2014237898B2/en active Active
- 2014-03-05 ES ES14711899.6T patent/ES2675404T3/es active Active
- 2014-03-05 SI SI201430741T patent/SI2970447T1/sl unknown
- 2014-03-05 PE PE2015001961A patent/PE20151531A1/es active IP Right Grant
- 2014-03-05 ES ES19190355T patent/ES2993153T3/es active Active
- 2014-03-05 ES ES18153438T patent/ES2769123T3/es active Active
- 2014-03-05 TR TR2018/07613T patent/TR201807613T4/tr unknown
- 2014-03-05 NZ NZ711704A patent/NZ711704A/en unknown
- 2014-03-05 ME MEP-2018-173A patent/ME03094B/me unknown
- 2014-03-05 HR HRP20181047TT patent/HRP20181047T1/hr unknown
- 2014-03-05 EA EA201591514A patent/EA029965B1/ru not_active IP Right Cessation
- 2014-03-05 JP JP2016500640A patent/JP6105146B2/ja active Active
- 2014-03-05 PL PL14711899T patent/PL2970447T3/pl unknown
- 2014-03-05 SG SG11201507686TA patent/SG11201507686TA/en unknown
- 2014-03-05 RS RS20180675A patent/RS57291B1/sr unknown
- 2014-03-05 PT PT147118996T patent/PT2970447T/pt unknown
- 2014-05-03 UA UAA201508673A patent/UA116008C2/uk unknown
-
2015
- 2015-08-31 TN TN2015000377A patent/TN2015000377A1/en unknown
- 2015-09-03 IL IL24116715A patent/IL241167B/en active IP Right Grant
- 2015-09-09 CL CL2015002531A patent/CL2015002531A1/es unknown
- 2015-09-14 PH PH12015502090A patent/PH12015502090B1/en unknown
-
2018
- 2018-07-24 CY CY20181100767T patent/CY1120459T1/el unknown
-
2019
- 2019-09-16 IL IL269387A patent/IL269387B/en active IP Right Grant
-
2022
- 2022-05-10 AR ARP220101240A patent/AR125831A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2970447T1 (sl) | Protitelesa proti pan-elr+ cxc kemokinom | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| CR20200601A (es) | Anticuerpos biespecificos contra dll3-cd3 | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20171324A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales | |
| AR102417A1 (es) | Anticuerpos biespecíficos anti-tnf- / anti-il-23 | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20140004A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| EA201290360A1 (ru) | Гуманизированные антитела против il-22ra человека | |
| EA201390738A1 (ru) | Нейтрализующие антитела против ccl20 |